You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

184 Results
Document
Jun 2020
Document
Jul 2020
Document
Jul 2020
Document
Jul 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    procarbazine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab (Unfunded),
methotrexate,
procarbazine,
cytarabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2020
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
trastuzumab,
oxaliplatin,
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2023
Document
Apr 2021
Document
May 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
riTUXimab (Unfunded),
methotrexate,
vinCRIStine,
procarbazine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2022
Guidelines and Advice
Status: Current
ID: GL 1-23-A
Jul 2021
Document
Sep 2021

Pages